Preclinical positron emission computed tomography of prolonged tumor growth after lutetium-177 prostate-specific membrane antigen treatment in xenograft model of human prostate cancer
- Authors: Klementyeva O.E.1, Lipengolts A.A.1, Grigorieva E.Y.1, Smirnova A.V.1,2, Finogenova Y.A.1,3, Shpakova K.E.1, Skribitsky V.A.1, Lagodzinskaya Y.S.1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology
- Moscow Clinical Scientific Center n.a. A.S. Loginov
- Peoples’ Friendship University of Russia
- Issue: Vol 28, No 1 (2023)
- Pages: 15-26
- Section: Original Study Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/217176
- DOI: https://doi.org/10.17816/onco501765
- ID: 217176
Cite item
Abstract
BACKGROUND: New treatment methods of castration-resistant prostate cancer with radionuclide therapy are needed. They will optimize personalized strategy for radionuclide therapy of metastatic castrate-resistant prostate cancer using low molecular weight ligands to prostate-specific membrane antigen (PSMA) labeled with lutetium-177.
AIM: To define the long-term effects and effectiveness of the treatment experimental animals with PET imaging to refine the research strategy.
METHODS: The study was performed in nu/nu male mice with PSMA-expressing 22Rv1 prostate cancer xenografts. Positron emission computed tomography with 18F-PSMA-1007 was used to confirm the tumor regrowth after a single therapeutic dose of [177Lu]Lu-PSMA-I&T.
RESULTS: Positron emission tomography imaging with 18F-PSMA-1007 showed the possibility of prolonged 22Rv1 tumor regrowth after a single injection of 9.2 MBq of [177Lu]Lu-PSMA-I&T, which is equivalent to minimal human therapeutic dose (28.6 MBq/kg).
CONCLUSIONS: The study confirmed the short period of the observed therapeutic effect after a single injection of 9.2 MBq of [177Lu]Lu-PSMA-I&T. The tumor regrowth in 2.5 months after the reduction of 22Rv1 xenografts to a non-palpable state was confirmed by positron emission computed tomography with 18F-PSMA-1007. These results confirm the need to study the frequency of repeated administrations of radiopharmaceuticals based on ligands to PSMA labeled with lutetium-177 to achieve a stable therapeutic effect in cases where a single dose reduction is necessary.
Full Text
##article.viewOnOriginalSite##About the authors
Olga E. Klementyeva
N.N. Blokhin National Medical Research Center of Oncology
Email: klementyeva.olga@gmail.com
ORCID iD: 0000-0002-6604-0860
SPIN-code: 6653-1201
Cand. Sci. (Bio.)
Russian Federation, 23 Kashirskoe shosse, 115478 MoscowAlexey A. Lipengolts
N.N. Blokhin National Medical Research Center of Oncology
Email: lipengolts@mail.ru
ORCID iD: 0000-0002-5631-9016
Cand. Sci. (Phys., Math.), Senior Research Associate
Russian Federation, 23 Kashirskoe shosse, 115478 MoscowElena Y. Grigorieva
N.N. Blokhin National Medical Research Center of Oncology
Email: grig-elen11@mail.ru
ORCID iD: 0000-0001-7726-7991
Dr. Sci. (Bio.)
Russian Federation, 23 Kashirskoe shosse, 115478 MoscowAnna V. Smirnova
N.N. Blokhin National Medical Research Center of Oncology; Moscow Clinical Scientific Center n.a. A.S. Loginov
Email: smirn-ova@mail.ru
ORCID iD: 0000-0003-0386-9732
SPIN-code: 4663-3199
Cand. Sci. (Bio.), Senior Research Associate
Russian Federation, 23 Kashirskoe shosse, 115478 Moscow; MoscowYulia A. Finogenova
N.N. Blokhin National Medical Research Center of Oncology; Peoples’ Friendship University of Russia
Author for correspondence.
Email: b-f.finogenova@yandex.ru
ORCID iD: 0000-0002-5144-1039
SPIN-code: 7597-2604
Research Associate
Russian Federation, 23 Kashirskoe shosse, 115478 Moscow; MoscowKristina E. Shpakova
N.N. Blokhin National Medical Research Center of Oncology
Email: shpakova.k.e@gmail.com
ORCID iD: 0000-0003-0246-1794
Russian Federation, 23 Kashirskoe shosse, 115478 Moscow
Vsevolod A. Skribitsky
N.N. Blokhin National Medical Research Center of Oncology
Email: skvseva@yandex.ru
ORCID iD: 0000-0003-2942-7895
SPIN-code: 8568-6890
Junior Research Associate
Russian Federation, 23 Kashirskoe shosse, 115478 MoscowYulia S. Lagodzinskaya
N.N. Blokhin National Medical Research Center of Oncology
Email: ishtar.lynx@gmail.com
ORCID iD: 0000-0001-6260-0763
SPIN-code: 3374-7453
Russian Federation, 23 Kashirskoe shosse, 115478 Moscow
References
- Crowley F, Sterpi M, Buckley C, et al. A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer. Research and Reports in Urology. 2021;13:457–472. doi: 10.2147/RRU.S264722
- Pituskin E, Fairchild A. Prostate Cancer with Bone Metastases: Addressing Chronic Pain from the Perspective of the Radiation Oncology Nurse Practitioner. Seminars in Oncology Nursing. 2021;37(4):151175. doi: 10.1016/j.soncn.2021.151175
- Mirshahvalad SA, Farzanefar S, Abbasi M. Therapeutic Outcomes of 177Lu-PSMA Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Single-Center Study. Asia Oceania Journal of Nuclear Medicine & Biology. 2023;11(1):23–29. doi: 10.22038/AOJNMB.2022.64964.1454
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine. [cited 2023 Oct 1]. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=177Lu+PSMA&cntry=&state=&city=&dist=&Search=Search
- Committee for Medicinal Products for Human Use (CHMP). Assessment report Pluvicto. 2022 Oct. EMA/871459/2022.
- Helmich LPH, de Arruda MAM, Sapienza MT. PSMA-directed radioligand therapy (PSMA-RLT) with Lutetium-177 (177Lu-PSMA) as a treatment to metastatic resistant prostate cancer: a systematic review. Revista De Medicina. 2021;100(4):391–402. doi: 10.11606/issn.1679-9836.v100i4p391-402
- Yusufi N, Wurzer A, Herz M, et al. Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T. Journal of Nuclear Medicine. 2021;62(8):1106–1111. doi: 10.2967/jnumed.120.254516
- Kuo H-T, Merkens H, Zhang Zh, et al. Enhancing Treatment Efficacy of 177Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies. Molecular Pharmaceutics. 2018;15(11):5183–5191. doi: 10.1021/acs.molpharmaceut.8b00720
- Weineisen M, Schottelius M, Simecek J, et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. Journal of Nuclear Medicine. 2015;56(8):1169–1176. doi: 10.2967/jnumed.115.158550
- Wang F (Nanjing First Hospital, Nanjing Medical University). 177Lu-PSMA-I&T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. National Library of Medicine (US), ClinicalTrials.gov; 2019 Jun. ID NCT04188587.
- Lückerath K, Wei L, Fendler WP, et al. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Research. 2018;8. doi: 10.1186/s13550-018-0451-z
- Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemotherapy and Pharmacology. 1989;24:148–154. doi: 10.1007/BF00300234
- Mironov AN, editor. Rukovodstvo po provedeniyu doklinicheskikh issledovanii lekarstvennykh sredstv. Part 1. Moscow: Grif i K; 2012. (In Russ).
- Khabriev RU, editor. Rukovodstvo po eksperimental’nomu (doklinicheskomu) izucheniyu novykh farmakologicheskikh veshchestv. 2nd edition. Moscow: Izdatelstvo Meditsina; 2008. (In Russ).
- IAEA Radioisotopes And Radiopharmaceuticals Series. Guidance for Preclinical Studies with Radiopharmaceuticals. 2021.
- Dupont P, Warwick J. Kinetic modelling in small animal imaging with PET. Methods. 2009;48(2):98–103. doi: 10.1016/j.ymeth.2009.03.008
- Kuntner C. Kinetic modeling in pre-clinical positron emission tomography. Zeitschrift für Medizinische Physik. 2014;24(4):274–285. doi: 10.1016/j.zemedi.2014.02.003
- Khmelinskii A, Baiker M, Kaijzel EL, et al. Articulated Whole-Body Atlases for Small Animal Image Analysis: Construction and Applications. Molecular Imaging and Biology. 2011;13:898–910. doi: 10.1007/s11307-010-0386-x
- Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Research. 1994;54(7):1807–1811.
- Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clinical cancer research. 1997;3(1):81–85.
- Malik D, Sood A, Mittal BR, et al. Nonspecific Uptake of 68Ga-Prostate-Specific Membrane Antigen in Diseases other than Prostate Malignancy on Positron Emission Tomography/Computed Tomography Imaging: A Pictorial Assay and Review of Literature. Indian Journal of Nuclear Medicine. 2018;33(4):317–325. doi: 10.4103/ijnm.IJNM_81_18
- de Galiza Barbosa F, Queiroz MA, Nunes RF, et al. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer imaging. 2020;20. doi: 10.1186/s40644-020-00300-7
- European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes. European Treaty Series — No. 123. Strasbourg. (Mar 18, 1986).
- Bol’shakov OP, Neznanov NG, Babakhanyan RV. Didakticheskie i eticheskie aspekty provedeniya issledovanii na biomodelyakh i na laboratornykh zhivotnykh. Kachestvennaya Klinicheskaya Praktika (Good Clinical Practice). 2002;(1):58–61. (In Russ).
- Directive 2010/63/EU of the European Parliament and of the Council on the protection of animals used for scientific purposes. (Sep 22, 2010).